On January 7, 2021, at noon EST, join leading experts in cancer immunotherapy as they discuss the latest advances in cancer immunotherapy emerging from ESMO Congress 2020.
This FREE CME-, CNE-, CPE-, and MOC-certified webinar is a chance for clinical oncologists, registered nurses, nurse practitioners, advanced practice registered nurses, pharmacists, physician assistants, emergency physicians, allied health professionals, other patient care providers, students, and patient advocates, to learn more about clinical advances from the ESMO Congress 2020.
After attending this webinar, participants will be able to:
- Describe advances in immune checkpoint inhibitor therapies for highly immunotherapy-responsive cancers including melanoma and renal cell carcinoma
- Outline novel immunotherapeutic strategies and implications for future cancer care
- Explain the rationale behind and implications of current combination immunotherapy studies
Webinar Faculty:
- Toni K. Choueiri, MD – Dana-Farber Cancer Institute
- Sumanta K. Pal, MD – City of Hope
- Lillian L. Siu, MD – Princess Margaret Cancer Centre, University Health Network
- Jeffery S. Weber, MD, PhD – NYU Langone Medical Center
Webinar Agenda:
- 12 – 12:05 p.m. ET Overview: welcome and introductions
- 12:05 – 12:40 p.m. ET Presentation and discussion of content from faculty experts
- 12:40–12:55 p.m. ET Question and answer session
- 12:55–1 p.m. ET Closing remarks
Continuing Education Credit Information:
Continuing Education Credits are available for physicians, nurses, and pharmacists. To view full accreditation information, click here.
The 2020-2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.